Mesoblast Limited
rexlemestrocel-L
chronic discogenic low back pain (CLBP)
Date
TBD
Advisory committee · Date TBD estimated
What's at stake
An FDA advisory committee reviews rexlemestrocel-L for chronic discogenic low back pain (CLBP) around Date TBD. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 6-K
verified 12h ago
“Mesoblast will seek to use its data from large randomized controlled trials in chronic discogenic low back pain (CLBP) and inflammatory chronic heart failure with low ejection fraction to support approvals for rexlemestrocel-L, aligning wit”